Citigroup
NPCE icon

Citigroup’s Neuropace NPCE Stock Holding History

Citigroup’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197K Buy
12,416
+11,369
+1,086% +$183K ﹤0.01% 4346
2026
Q1 		$13.8K Buy
1,047
+471
+82% +$7.07K ﹤0.01% 4927
2025
Q4 		$8.89K Sell
576
-458
-44% -$6.13K ﹤0.01% 5096
2025
Q3 		$10.7K Sell
1,034
-7,560
-88% -$71.3K ﹤0.01% 5007
2025
Q2 		$95.7K Sell
8,594
-1,500
-15% -$18.8K ﹤0.01% 4423
2025
Q1 		$124K Sell
10,094
-1,013
-9% -$12.7K ﹤0.01% 4480
2024
Q4 		$124K Buy
11,107
+1,263
+13% +$11K ﹤0.01% 4722
2024
Q3 		$68.6K Buy
9,844
+6,875
+232% +$50.3K ﹤0.01% 4915
2024
Q2 		$22.4K Sell
2,969
-72,719
-96% -$734K ﹤0.01% 4973
2024
Q1 		$999K Buy
75,688
+40,667
+116% +$580K ﹤0.01% 3026
2023
Q4 		$361K Buy
35,021
+32,037
+1,074% +$255K ﹤0.01% 3618
2023
Q3 		$29K Buy
+2,984
New +$17.5K ﹤0.01% 4292
2022
Q3 		– Sell
-62
Closed – – 6172
2022
Q2 		$0 Sell
62
-194
-76% -$1.28K ﹤0.01% 6518
2022
Q1 		$2K Sell
256
-1,583
-86% -$13.7K ﹤0.01% 6080
2021
Q4 		$19K Buy
1,839
+1,021
+125% +$13.3K ﹤0.01% 5399
2021
Q3 		$13K Buy
818
+487
+147% +$10.2K ﹤0.01% 5404
2021
Q2 		$8K Buy
+331
New +$7.68K ﹤0.01% 5741

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Citigroup's NPCE Position: Q2 2026 in Review

Citigroup increased its Neuropace (NPCE) stake by 1,086% in Q2 2026, buying an estimated $183K and bringing the position to 12,416 shares worth $197K. The position accounts for ﹤0.01% of the portfolio, ranked #4346.

Citigroup first reported a position in NPCE in Q2 2021 and has held it in 17 quarters since. The position peaked at $999K in Q1 2024. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Citigroup held 12,416 shares of Neuropace worth $197K as of Q2 2026.
  • Citigroup bought 11,369 Neuropace shares in Q2 2026, an estimated $183K.
  • Neuropace made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4346 holding.
  • Citigroup first reported a position in Neuropace in Q2 2021 and has held it in 17 quarters since.
  • Citigroup's Neuropace position peaked at $999K in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.